Pathstone Holdings
LAB icon

Pathstone Holdings’s Standard BioTools LAB Stock Holding History

Pathstone Holdings’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,158
Closed -$15.6K – 2288
2025
Q4 		$15.6K Hold
12,158
– – ﹤0.01% 2213
2025
Q3 		$15.8K Hold
12,158
– – ﹤0.01% 2324
2025
Q2 		$14.6K Buy
+12,158
New +$13.5K ﹤0.01% 2179

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Pathstone Holdings's LAB Position: Q1 2026 in Review

Pathstone Holdings sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 12,158 shares — an estimated $15.6K sold.

Pathstone Holdings first reported a position in LAB in Q2 2025 and held it in 3 quarters. The position peaked at $15.8K in Q3 2025. 156 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Pathstone Holdings reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
  • Pathstone Holdings sold 12,158 Standard BioTools shares in Q1 2026, an estimated $15.6K.
  • Pathstone Holdings first reported a position in Standard BioTools in Q2 2025 and held it in 3 quarters.
  • Pathstone Holdings's Standard BioTools position peaked at $15.8K in Q3 2025.
  • 156 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.